About Biofire Diagnostics
Biofire Diagnostics is a company based in Salt Lake City (United States) founded in 1990 was acquired by Institut Merieux in December 2021. Biofire Diagnostics has raised $84 million across 6 funding rounds from investors including HHS, BioMerieux and 10X Capital. Biofire Diagnostics offers products and services including BIOFIRE System, Respiratory Panel, and Gastrointestinal Panel. Biofire Diagnostics operates in a competitive market with competitors including ChromaCode, Inflammatix, Visby Medical, MeMed and GenMark Diagnostics, among others.
- Headquarter Salt Lake City, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biofire Diagnostics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$84 M (USD)
in 6 rounds
-
Latest Funding Round
$14 M (USD), Series A
Nov 07, 2022
-
Investors
HHS
& 10 more
-
Employee Count
Employee Count
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biofire Diagnostics
Biofire Diagnostics offers a comprehensive portfolio of products and services, including BIOFIRE System, Respiratory Panel, and Gastrointestinal Panel.
Multiplex PCR system for rapid infectious disease testing.
Detects viruses and bacteria in respiratory samples.
Identifies pathogens in gastrointestinal infections.
Funding Insights of Biofire Diagnostics
Biofire Diagnostics has successfully raised a total of $84M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $14 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series A — $14.0M
-
First Round
First Round
(19 Sep 2012)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2022 | Amount | Series A - Biofire Diagnostics | Valuation | Founders Fund | |
| Mar, 2015 | Amount | Grant - Biofire Diagnostics | Valuation |
investors |
|
| Aug, 2014 | Amount | Grant - Biofire Diagnostics | Valuation |
investors |
Investors in Biofire Diagnostics
Biofire Diagnostics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, BioMerieux and 10X Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and defense sectors.
|
Founded Year | Domain | Location | |
|
Access to private investment strategies is provided for institutional investors.
|
Founded Year | Domain | Location | |
|
Venture capital investing with a focus on diversity and inclusion in the ecosystem.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biofire Diagnostics
Financial Statements - Biofire Diagnostics
Biofire Diagnostics Comparisons
Competitors of Biofire Diagnostics
Biofire Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ChromaCode, Inflammatix, Visby Medical, MeMed and GenMark Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital molecular biology analytics are developed for disease management.
|
|
| domain | founded_year | HQ Location |
Provider of diagnostic solutions for systemic infections
|
|
| domain | founded_year | HQ Location |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| domain | founded_year | HQ Location |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| domain | founded_year | HQ Location |
Point-of-care molecular platforms for infectious disease detection are developed.
|
Frequently Asked Questions about Biofire Diagnostics
Biofire Diagnostics was founded in 1990 and raised its 1st funding round 22 years after it was founded.
Biofire Diagnostics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Biofire Diagnostics is a funded company, having raised a total of $84M across 6 funding rounds to date. The company's 1st funding round was a Grant of $168K, raised on Sep 19, 2012.
Biofire Diagnostics was founded in 1990 and is headquartered in Salt Lake City, United States. Operations center on the molecular diagnostics sector, where new assays are developed for the proprietary FilmArray System, a multiplex PCR platform. Panels offered include Respiratory (RP), Blood Culture Identification (BCID), Gastrointestinal (GI), and MeningitisEncephalitis (ME) tests for pathogen detection.
Biofire Diagnostics's top competitors include ChromaCode, Visby Medical and Inflammatix.
Biofire Diagnostics offers BIOFIRE System, Respiratory Panel, and Gastrointestinal Panel.
Biofire Diagnostics has 11 investors. Key investors include HHS, BioMerieux, 10X Capital, Institut Mérieux, and Gavin de Becker and Associates.